Antigen na 17.a2 + melanoma differentiat

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
18001
TRIAL 18001-88001 Randomized phase III study of adjuvant immunization with NA17.A2 and melanoma differentiation peptides in HLA-A2 patients with primary ocular melanoma at high risk of relapse.

Back to Protocol section